152 related articles for article (PubMed ID: 25808135)
21. Studies of N(9)-arenthenyl purines as novel DFG-in and DFG-out dual Src/Abl inhibitors using 3D-QSAR, docking and molecular dynamics simulations.
Ma S; Zeng G; Fang D; Wang J; Wu W; Xie W; Tan S; Zheng K
Mol Biosyst; 2015 Feb; 11(2):394-406. PubMed ID: 25406390
[TBL] [Abstract][Full Text] [Related]
22. Identification of abelson tyrosine kinase inhibitors as potential therapeutics for Alzheimer's disease using multiple e-pharmacophore modeling and molecular dynamics.
Palakurti R; Vadrevu R
J Biomol Struct Dyn; 2017 Mar; 35(4):883-896. PubMed ID: 26982633
[TBL] [Abstract][Full Text] [Related]
23. Insights into the conformational switching mechanism of the human vascular endothelial growth factor receptor type 2 kinase domain.
Chioccioli M; Marsili S; Bonaccini C; Procacci P; Gratteri P
J Chem Inf Model; 2012 Feb; 52(2):483-91. PubMed ID: 22229497
[TBL] [Abstract][Full Text] [Related]
24. In-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study.
Kumar H; Raj U; Gupta S; Varadwaj PK
J Biomol Struct Dyn; 2016 Oct; 34(10):2171-83. PubMed ID: 26479578
[TBL] [Abstract][Full Text] [Related]
25. Rational Drug Design Approach of Receptor Tyrosine Kinase Type III Inhibitors.
Kim C; Kim E
Curr Med Chem; 2019; 26(42):7623-7640. PubMed ID: 29932031
[TBL] [Abstract][Full Text] [Related]
26. Assessing an ensemble docking-based virtual screening strategy for kinase targets by considering protein flexibility.
Tian S; Sun H; Pan P; Li D; Zhen X; Li Y; Hou T
J Chem Inf Model; 2014 Oct; 54(10):2664-79. PubMed ID: 25233367
[TBL] [Abstract][Full Text] [Related]
27. Discovery of dual ZAP70 and Syk kinases inhibitors by docking into a rare C-helix-out conformation of Syk.
Zhao H; Caflisch A
Bioorg Med Chem Lett; 2014 Mar; 24(6):1523-7. PubMed ID: 24569110
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of Janus kinases by tyrosine phosphorylation inhibitor, Tyrphostin AG-490.
Rashid S; Bibi N; Parveen Z; Shafique S
J Biomol Struct Dyn; 2015; 33(11):2368-79. PubMed ID: 26017266
[TBL] [Abstract][Full Text] [Related]
29. CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice.
Xin X; Abrams TJ; Hollenbach PW; Rendahl KG; Tang Y; Oei YA; Embry MG; Swinarski DE; Garrett EN; Pryer NK; Trudel S; Jallal B; Mendel DB; Heise CC
Clin Cancer Res; 2006 Aug; 12(16):4908-15. PubMed ID: 16914579
[TBL] [Abstract][Full Text] [Related]
30. Docking simulation study and kinase selectivity of f152A1 and its analogs.
Ikemori-Kawada M; Inoue A; Goto M; Wang YJ; Kawakami Y
J Chem Inf Model; 2012 Aug; 52(8):2059-68. PubMed ID: 22830536
[TBL] [Abstract][Full Text] [Related]
31. DFGmodel: predicting protein kinase structures in inactive states for structure-based discovery of type-II inhibitors.
Ung PM; Schlessinger A
ACS Chem Biol; 2015 Jan; 10(1):269-78. PubMed ID: 25420233
[TBL] [Abstract][Full Text] [Related]
32. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.
Hart KC; Robertson SC; Kanemitsu MY; Meyer AN; Tynan JA; Donoghue DJ
Oncogene; 2000 Jul; 19(29):3309-20. PubMed ID: 10918587
[TBL] [Abstract][Full Text] [Related]
33. NMR-based approach to measure the free energy of transmembrane helix-helix interactions.
Mineev KS; Lesovoy DM; Usmanova DR; Goncharuk SA; Shulepko MA; Lyukmanova EN; Kirpichnikov MP; Bocharov EV; Arseniev AS
Biochim Biophys Acta; 2014 Jan; 1838(1 Pt B):164-72. PubMed ID: 24036227
[TBL] [Abstract][Full Text] [Related]
34. 1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest.
Miyake M; Ishii M; Koyama N; Kawashima K; Kodama T; Anai S; Fujimoto K; Hirao Y; Sugano K
J Pharmacol Exp Ther; 2010 Mar; 332(3):795-802. PubMed ID: 19955487
[TBL] [Abstract][Full Text] [Related]
35. FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies.
Chen J; Lee BH; Williams IR; Kutok JL; Mitsiades CS; Duclos N; Cohen S; Adelsperger J; Okabe R; Coburn A; Moore S; Huntly BJ; Fabbro D; Anderson KC; Griffin JD; Gilliland DG
Oncogene; 2005 Dec; 24(56):8259-67. PubMed ID: 16091734
[TBL] [Abstract][Full Text] [Related]
36. Theoretical study on the interaction of pyrrolopyrimidine derivatives as LIMK2 inhibitors: insight into structure-based inhibitor design.
Shen M; Zhou S; Li Y; Li D; Hou T
Mol Biosyst; 2013 Oct; 9(10):2435-46. PubMed ID: 23881296
[TBL] [Abstract][Full Text] [Related]
37. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations.
Chohan TA; Chen JJ; Qian HY; Pan YL; Chen JZ
Mol Biosyst; 2016 Apr; 12(4):1250-68. PubMed ID: 26883408
[TBL] [Abstract][Full Text] [Related]
38. Discovery of ZAP70 inhibitors by high-throughput docking into a conformation of its kinase domain generated by molecular dynamics.
Zhao H; Caflisch A
Bioorg Med Chem Lett; 2013 Oct; 23(20):5721-6. PubMed ID: 23993776
[TBL] [Abstract][Full Text] [Related]
39. Ensemble-Based Replica Exchange Alchemical Free Energy Methods: The Effect of Protein Mutations on Inhibitor Binding.
Bhati AP; Wan S; Coveney PV
J Chem Theory Comput; 2019 Feb; 15(2):1265-1277. PubMed ID: 30592603
[TBL] [Abstract][Full Text] [Related]
40. Molecular modeling studies on series of Btk inhibitors using docking, structure-based 3D-QSAR and molecular dynamics simulation: a combined approach.
Balasubramanian PK; Balupuri A; Cho SJ
Arch Pharm Res; 2016 Mar; 39(3):328-39. PubMed ID: 26699616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
